LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors’s Pacira BioSciences PCRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $9.56K | Hold |
400
| – | – | ﹤0.01% | 483 |
|
|
2025
Q1 | $10.1K | Hold |
400
| – | – | ﹤0.01% | 483 |
|
|
2024
Q4 | $10.3K | Hold |
400
| – | – | ﹤0.01% | 488 |
|
|
2024
Q3 | $6.81K | Hold |
400
| – | – | ﹤0.01% | 512 |
|
|
2024
Q2 | $8.55K | Hold |
400
| – | – | ﹤0.01% | 498 |
|
|
2024
Q1 | $10.4K | Hold |
400
| – | – | ﹤0.01% | 492 |
|
|
2023
Q4 | $13K | Sell |
400
-20,600
| -98% | -$671K | ﹤0.01% | 486 |
|
|
2023
Q3 | $613K | Sell |
21,000
-1,000
| -5% | -$29.2K | 0.01% | 180 |
|
|
2023
Q2 | $882K | Sell |
22,000
-8,948
| -29% | -$359K | 0.01% | 158 |
|
|
2023
Q1 | $1.26M | Sell |
30,948
-4,782
| -13% | -$195K | 0.01% | 140 |
|
|
2022
Q4 | $1.38M | Sell |
35,730
-15,534
| -30% | -$600K | 0.02% | 133 |
|
|
2022
Q3 | $2.73M | Sell |
51,264
-178
| -0.3% | -$9.47K | 0.04% | 100 |
|
|
2022
Q2 | $3M | Buy |
51,442
+7,532
| +17% | +$439K | 0.04% | 100 |
|
|
2022
Q1 | $3.35M | Buy |
43,910
+2
| +0% | +$153 | 0.03% | 103 |
|
|
2021
Q4 | $2.64M | Buy |
43,908
+8,295
| +23% | +$499K | 0.02% | 112 |
|
|
2021
Q3 | $1.99M | Buy |
35,613
+15,086
| +73% | +$845K | 0.02% | 123 |
|
|
2021
Q2 | $1.25M | Buy |
20,527
+16,102
| +364% | +$977K | 0.01% | 157 |
|
|
2021
Q1 | $310K | Buy |
4,425
+4,330
| +4,558% | +$303K | ﹤0.01% | 251 |
|
|
2020
Q4 | $6K | Buy |
+95
| New | +$6K | ﹤0.01% | 676 |
|
|
2017
Q4 | – | Sell |
-19
| Closed | – | – | 840 |
|
|
2017
Q3 | $0 | Buy |
+19
| New | – | ﹤0.01% | 876 |
|